ClinicalTrials.gg
WithdrawnNCT00576225Updated Oct 19, 2020

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

A Phase 3 interventional study of CT-2103/carboplatin and paclitaxel/carboplatin in NSCLC, sponsored by CTI BioPharma. Withdrawn at 44 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2007, registered Dec 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels >30 pg/ml.

02

Conditions studied

  • NSCLC

Keywords

  • NSCLC
  • women
  • CT-2103
  • paclitaxel
  • carboplatin
03

In context

Lead sponsor

CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with baseline estradiol >25 pg/mL
  2. - or cytologically-confirmed diagnosis of NSCLC.
  3. performance score (PS) of 0, 1, or 2.
  4. Patients must meet one of the following criteria have either (1) Recurrent disease following completion of radiation or surgery, (2) Stage IIIB disease and not be a candidate for combined modality therapy (primary radiation therapy or surgery), or (3) Stage IV disease.
  5. At least 18 years of age.
  6. Adequate bone marrow function
  7. Adequate renal function
  8. Adequate hepatic function
  9. ≥12 weeks

Exclusion criteria

Exclusion Criteria:

  1. Known to the or the study drug (either CT-2103, paclitaxel, or carboplatin that the patient will receive.
  2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology.
  3. Weight loss >10% in previous 6 months
  4. LDH > 2.5X IULN
  5. Both LDH > 1.5X IULN and ≥ 5% weight loss in previous 6 months
  6. >35
  7. Any prior systemic chemotherapy for the treatment of lung cancer. This includes systemic radiosensitizers used to treat and any biologic agent.
  8. Local palliative radiotherapy \< 7 days before randomization.
  9. Radiation with curative intent \< 30 days before randomization.
  10. Concurrent primary except for carcinoma in situ or non-melanoma skin cancer.
  11. Grade 2 or greater neuropathy.
  12. Evidence of significant unstable neurological symptoms within the 4 weeks before study randomization.
  13. active infection for which active therapy is underway.
  14. therapy within 4 weeks before randomization, unless local requirements are more stringent.
  15. Unstable medical conditions including unstable angina or myocardial infarction within the past 6 months before randomization.
  16. Pregnant women or nursing mothers.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental

    Drug: CT-2103/carboplatin

  • Active comparator
    Control

    Drug: paclitaxel/carboplatin

Interventions

  • DrugCT-2103/carboplatin

    Drug pages: Paclitaxel poliglumex · Carboplatin

    CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.

  • Drugpaclitaxel/carboplatin

    Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. Survival

    Time frame: up to 3 years post treatment

Secondary outcomes

  1. progression-free survival, disease control, clinical benefit, response rate, quality of life, and the safety

    Time frame: up to 3 years post treatment

07

Study locations

44 sites
  • Scottsdale Medical Specialists
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Hembree Regional Cancer Center
    Fort Smith, Arkansas 72903, United States
  • Providence St. Joseph Medical Center
    Burbank, California 91505, United States
  • Southwest Cancer Care
    Escondido, California 92025, United States
  • Clinical Trials & Research Institute
    Montebello, California 90640, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Broward Oncology Associates
    Fort Lauderdale, Florida 33308, United States
  • Horizon Institute for Clinical Research
    Hollywood, Florida 33021, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Pasco Pinellas Cancer Center
    Tarpon Springs, Florida 34691, United States
  • Joliet Oncology Hematology Associates, Ltd
    Joliet, Illinois 60435, United States
  • Loyola University
    Maywood, Illinois 60153, United States
  • Hematology Oncology Consultants
    Naperville, Illinois 60540, United States
  • Cancer Care Center
    New Albany, Indiana 47150, United States
  • Providence Medical Group
    Terre Haute, Indiana 47802, United States
  • Family Medicine of Vincennes Clinical Trials Center
    Vincennes, Indiana 47591, United States
  • Kansas City Cancer Center
    Overland Park, Kansas 66210, United States
  • Henry Ford Health System, Josephine Ford Cancer Center
    Detroit, Michigan 48202, United States
  • W. Michigan Regional Cancer & Blood Center
    Free Soil, Michigan 49411, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Columbia Comprehensive Cancer Care Clinics
    Jefferson City, Missouri 65109, United States
  • St. Louis University
    Saint Louis, Missouri 63110, United States
  • Las Vegas Cancer Center
    Henderson, Nevada 89052, United States
  • VA Sierra Nevada Health Care System
    Reno, Nevada 89502, United States
  • Lincoln Medical and Mental Health Center
    New York, New York 10451, United States
  • Arena Oncology Associates
    New York, New York 11042, United States
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • St Alexius Medical Center
    Bismarck, North Dakota 58501, United States
  • Blood and Cancer Center
    Canfield, Ohio 44406, United States
  • Aultman Hospital Clinical Trials
    Canton, Ohio 44710, United States
  • UIMA, Inc / University of Cincinnati-Barrett Cancer Center
    Cincinnati, Ohio 45267, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73117, United States
  • Vita Hematology Oncology, P.C.
    Fountain Hill, Pennsylvania 18105, United States
  • The Family Cancer Center
    Collierville, Tennessee 38017, United States
  • Mid-South Cancer Center
    Germantown, Tennessee 38138, United States
  • Southwest Regional Cancer Center
    Austin, Texas 78705, United States
  • Lone Star Oncology Consultants
    Austin, Texas 78759, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75246, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Cancer Outreach Associates, LLC
    Arlington, Virginia 24211, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98111, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2007 to primary completion in Apr 2010, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2007
First posted
Dec 19, 2007
StartActual
Sep 2007
Primary completionActual
Apr 5, 2010
CompletionActual
Apr 5, 2010
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00576225
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Sep 2007
Primary completion
Apr 5, 2010
Completion
Apr 5, 2010
Last update
Oct 19, 2020

Study contacts

Jack W. Singer, M.D.
study director · CTI BioPharma

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel poliglumex · Carboplatin

Start the discussion